Healthcare
Johnson & Johnson(JNJ)
Live Price
Offline$228.39
-2.48% today
1Y Change
+50.93%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $548.73B
- Revenue Growth
- +6.0%
- EPS Growth
- +88.9%
- Dividend Yield
- 2.3%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Johnson & Johnson (JNJ) is a Healthcare stock with a market cap of $548.73B and listed on NYSE. The stock last traded around $228.39 and up 50.9% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +6.0%, EPS growth of +88.9%, a dividend yield of 2.3%. What stands out right now is revenue +6.0%, EPS +88.9%, free cash flow -0.7% with operating margin 26.9% and ROIC 13.6%. The dividend is present but secondary, with a yield around 2.3%. Valuation sits in the middle of the pack at P/E 26.5 and price/sales 5.7. Stock Foundry combines JNJ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.0% vs +7.6% peer median
Operating Margin
Above sector median
+26.9% vs +19.4% peer median
P/E
Below sector median
26.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.0% and EPS at +88.9%, with operating margin around 26.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 14, 2026 | โ | -0.6% | -5.8% | -6.6% |
2026 Jan 21, 2026 | +0.0% | +0.2% | +4.5% | +13.3% |
2025 Oct 14, 2025 | +1.4% | +0.2% | +0.5% | +1.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
JNJ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
JNJ Max Drawdown
-10.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JNJ and SPY.
Company Overview
Johnson & Johnson
New York Stock Exchange
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
- Leadership
- Joaquin Duato
- IPO Date
- Jan 2, 1943
- Employees
- 138.1k
- Street Address
- One Johnson & Johnson Plaza
- Mailing
- New Brunswick, NJ, 08933
- Region
- New Brunswick, NJ, US
- Reporting Currency
- USD
- Investor Line
- 732 524 0400
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 26.5
- EV/EBITDA
- 17.2
- Price/Sales
- 5.7
- Price/Book
- 6.9
Growth
- Revenue
- +6.0%
- EPS
- +88.9%
- Free Cash Flow
- -0.7%
Profitability
- Gross Margin
- 69.1%
- Operating Margin
- 26.9%
- Net Margin
- 21.8%
- ROE
- 26.3%
- ROIC
- 13.6%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 1.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.